SpyGlass Pharma is a late-stage biopharmaceutical company focused on intraocular drug delivery platforms. Its Techology centers on an IOL-mounted, controlled-release system designed to deliver years of ophthalmic therapy, notably bimatoprost, to treat glaucoma patients undergoing cataract surgery. The platform aims to improve patient adherence and outcomes by providing consistent daily drug release within the eye. Headquartered in California, SpyGlass targets ophthalmic indications through implanted devices delivered during standard cataract procedures.